HC Wainwright Issues Pessimistic Forecast for BDTX Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Research analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Black Diamond Therapeutics in a research report issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.32) for the quarter, down from their prior forecast of ($0.31). HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Black Diamond Therapeutics' current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics' Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03.

BDTX has been the subject of several other reports. Stifel Nicolaus lowered their target price on Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a report on Friday, March 7th. Wedbush reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday, March 19th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Black Diamond Therapeutics currently has an average rating of "Buy" and an average target price of $14.60.

Remove Ads

Black Diamond Therapeutics Trading Down 5.6 %

Shares of NASDAQ BDTX traded down $0.10 during trading hours on Thursday, reaching $1.68. The stock had a trading volume of 3,533,871 shares, compared to its average volume of 1,385,229. Black Diamond Therapeutics has a 52-week low of $1.59 and a 52-week high of $7.66. The firm has a market cap of $95.19 million, a price-to-earnings ratio of -1.26 and a beta of 2.52. The business's fifty day moving average price is $2.16 and its two-hundred day moving average price is $2.85.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. D. E. Shaw & Co. Inc. acquired a new stake in Black Diamond Therapeutics in the fourth quarter valued at approximately $37,000. Intech Investment Management LLC boosted its position in shares of Black Diamond Therapeutics by 49.1% in the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company's stock worth $41,000 after purchasing an additional 6,340 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Black Diamond Therapeutics by 429.6% during the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock worth $41,000 after buying an additional 15,355 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Black Diamond Therapeutics in the fourth quarter valued at about $42,000. Finally, Wells Fargo & Company MN boosted its holdings in Black Diamond Therapeutics by 41.8% in the fourth quarter. Wells Fargo & Company MN now owns 20,119 shares of the company's stock worth $43,000 after acquiring an additional 5,932 shares in the last quarter. Hedge funds and other institutional investors own 95.47% of the company's stock.

Insider Activity

In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the business's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total value of $11,973,484.44. Following the completion of the transaction, the insider now directly owns 2,733,547 shares in the company, valued at approximately $5,658,442.29. The trade was a 67.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 8.87% of the company's stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.